Solifenacin Succinate Tablets, 10 mg, 30-count bottles, Rx Only, Manufactured by: Cipla Ltd., Ver...

FDA Drug Recall #D-0660-2021 — Class II — June 10, 2021

Recall Summary

Recall Number D-0660-2021
Classification Class II — Moderate risk
Date Initiated June 10, 2021
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm CIPLA
Location Warren, NJ
Product Type Drugs
Quantity 7228 bottles

Product Description

Solifenacin Succinate Tablets, 10 mg, 30-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna, Goa, India Manufactured for Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL, 33323, NDC 69097-261-02.

Reason for Recall

CGMP Deviations

Distribution Pattern

Nationwide within the United States

Lot / Code Information

Lot #: GG90819, Exp. Date 06/2021

Other Recalls from CIPLA

Recall # Classification Product Date
D-1550-2022 Class II Arformoterol Tartrate Inhalation Solution, 15 m... Sep 29, 2022
D-1545-2022 Class II Budesonide Inhalation Suspension 0.25mg/2mL, Fo... Sep 15, 2022
D-1498-2022 Class II Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL ... Aug 22, 2022
D-1499-2022 Class II Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL ... Aug 22, 2022
D-1328-2022 Class II Difluprednate Ophthalmic Emulsion 0.05%, For Op... Aug 2, 2022

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.